Skip to main content

Table 1 Comparison of systemic therapy for advanced (unresectable stage III or stage IV) melanoma

From: Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Treatment RR (%) PFS (med), months OS (med/2-years)
Single-agent BRAFi 50 6–8 18.7 months/~ 40%
Combo BRAFi and MEKi 65–70 9–12 15 months/~ 50%
Ipilimumab 10 2–3 12 months/~ 30%
(20% 5 year survival)
Anti-PD-1 mAb (nivolumab or pembrolizumab) 25–45 ~ 6 18–24 months/~ 50%
Combo ipilimumab and nivolumab ~ 60 11–12 Unk./~ 64%